203 related articles for article (PubMed ID: 15583032)
1. Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma.
Thomas DM; Johnson SA; Sims NA; Trivett MK; Slavin JL; Rubin BP; Waring P; McArthur GA; Walkley CR; Holloway AJ; Diyagama D; Grim JE; Clurman BE; Bowtell DD; Lee JS; Gutierrez GM; Piscopo DM; Carty SA; Hinds PW
J Cell Biol; 2004 Dec; 167(5):925-34. PubMed ID: 15583032
[TBL] [Abstract][Full Text] [Related]
2. Impaired cell cycle regulation of the osteoblast-related heterodimeric transcription factor Runx2-Cbfbeta in osteosarcoma cells.
San Martin IA; Varela N; Gaete M; Villegas K; Osorio M; Tapia JC; Antonelli M; Mancilla EE; Pereira BP; Nathan SS; Lian JB; Stein JL; Stein GS; van Wijnen AJ; Galindo M
J Cell Physiol; 2009 Dec; 221(3):560-71. PubMed ID: 19739101
[TBL] [Abstract][Full Text] [Related]
3. A role for the retinoblastoma protein as a regulator of mouse osteoblast cell adhesion: implications for osteogenesis and osteosarcoma formation.
Sosa-García B; Gunduz V; Vázquez-Rivera V; Cress WD; Wright G; Bian H; Hinds PW; Santiago-Cardona PG
PLoS One; 2010 Nov; 5(11):e13954. PubMed ID: 21085651
[TBL] [Abstract][Full Text] [Related]
4. BRD4 binds to active cranial neural crest enhancers to regulate RUNX2 activity during osteoblast differentiation.
Musa RE; Lester KL; Quickstad G; Vardabasso S; Shumate TV; Salcido RT; Ge K; Shpargel KB
Development; 2024 Jan; 151(2):. PubMed ID: 38063851
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of CtIP leads to early embryonic lethality mediated by G1 restraint and to tumorigenesis by haploid insufficiency.
Chen PL; Liu F; Cai S; Lin X; Li A; Chen Y; Gu B; Lee EY; Lee WH
Mol Cell Biol; 2005 May; 25(9):3535-42. PubMed ID: 15831459
[TBL] [Abstract][Full Text] [Related]
6. Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts.
Pautke C; Schieker M; Tischer T; Kolk A; Neth P; Mutschler W; Milz S
Anticancer Res; 2004; 24(6):3743-8. PubMed ID: 15736406
[TBL] [Abstract][Full Text] [Related]
7. The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive.
Kast RE
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895152
[TBL] [Abstract][Full Text] [Related]
8. RUNX Family as a Promising Biomarker and a Therapeutic Target in Bone Cancers: A Review on Its Molecular Mechanism(s) behind Tumorigenesis.
Vimalraj S; Sekaran S
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370857
[TBL] [Abstract][Full Text] [Related]
9. Assembling the Puzzle Pieces. Insights for in Vitro Bone Remodeling.
Krasnova O; Neganova I
Stem Cell Rev Rep; 2023 Aug; 19(6):1635-1658. PubMed ID: 37204634
[TBL] [Abstract][Full Text] [Related]
10. Muscle Regeneration in Holothurians without the Upregulation of Muscle Genes.
Nizhnichenko VA; Boyko AV; Ginanova TT; Dolmatov IY
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555677
[TBL] [Abstract][Full Text] [Related]
11. Preparation of porous calcium phosphate microspheres with phosphate-containing molecules at room temperature for drug delivery and osteogenic differentiation.
Liu JF; Wei L; Duolikun D; Hou XD; Chen F; Liu JJ; Zheng LP
RSC Adv; 2018 Jul; 8(45):25480-25488. PubMed ID: 35539788
[TBL] [Abstract][Full Text] [Related]
12. The influence of the morphology of titania and hydroxyapatite on the proliferation and osteogenic differentiation of human mesenchymal stem cells.
Kuvyrkou YU; Brezhneva N; Skorb EV; Ulasevich SA
RSC Adv; 2021 Jan; 11(7):3843-3853. PubMed ID: 35424371
[TBL] [Abstract][Full Text] [Related]
13.
Ha N; Sun J; Bian Q; Wu D; Wang X
Front Physiol; 2022; 13():819619. PubMed ID: 35242053
[TBL] [Abstract][Full Text] [Related]
14. The Multiple Interactions of RUNX with the Hippo-YAP Pathway.
Chuang LSH; Ito Y
Cells; 2021 Oct; 10(11):. PubMed ID: 34831147
[TBL] [Abstract][Full Text] [Related]
15. Limonoid Triterpene, Obacunone Increases Runt-Related Transcription Factor 2 to Promote Osteoblast Differentiation and Function.
Park KR; Kim S; Cho M; Yun HM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33801166
[TBL] [Abstract][Full Text] [Related]
16. Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.
Lilienthal I; Herold N
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961800
[TBL] [Abstract][Full Text] [Related]
17. MicroRNAs signatures, bioinformatics analysis of miRNAs, miRNA mimics and antagonists, and miRNA therapeutics in osteosarcoma.
Otoukesh B; Abbasi M; Gorgani HO; Farahini H; Moghtadaei M; Boddouhi B; Kaghazian P; Hosseinzadeh S; Alaee A
Cancer Cell Int; 2020; 20():254. PubMed ID: 32565738
[TBL] [Abstract][Full Text] [Related]
18. Molecular Mechanism of Runx2-Dependent Bone Development.
Komori T
Mol Cells; 2020 Feb; 43(2):168-175. PubMed ID: 31896233
[TBL] [Abstract][Full Text] [Related]
19. The Role of Ubiquitination in Regulating Embryonic Stem Cell Maintenance and Cancer Development.
Wang D; Bu F; Zhang W
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151253
[TBL] [Abstract][Full Text] [Related]
20. Regulation of Proliferation, Differentiation and Functions of Osteoblasts by Runx2.
Komori T
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
